Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Trials (London, England)|November 14, 2023
Reporting and impact of subsequent cycle toxicities in oncology phase I clinical trialsAvina Rami, Steven G DuBois, Kevin Campbell
International Journal of Molecular Sciences|January 1, 2021
Reprogramming and Differentiation of Cutaneous Squamous Cell Carcinoma Cells in Recessive Dystrophic Epidermolysis BullosaAvina Rami, Łukasz Łaczmański, Jagoda Jacków-Nowicka, et al.
Cancer Medicine|September 8, 2025
Contemporary Characteristics and Outcomes of Pediatric Oncology Patients Participating in Early Phase Clinical TrialsAvina Rami, Kira Bona, Suzanne Shusterman, et al.
JCO Oncology Practice|April 24, 2026
Efficacy and Safety of 177Lu-PSMA-617 in Elderly Patients With Metastatic Castration-Resistant Prostate CancerDaniel Sentana-Lledo, Avina Rami, Caiwei Zhong, et al.
Bioengineering & Translational Medicine|February 3, 2022
Engineering human skin model innervated with itch sensory neuron-like cells differentiated from induced pluripotent stem cellsZongyou Guo, Chi-Kun Tong, Joanna Jacków, et al.
Mededportal : the Journal of Teaching and Learning Resources|June 25, 2025
Peer-to-Peer Mental Health Training: A National Model for Peer Support for Medical and Dental StudentsArmand Amini, Avina Rami, Rhea W Teng, et al.
Cancers|June 26, 2025
Race and Outcomes to [<sup>177</sup>Lu]Lu-PSMA-617 in Advanced Prostate CancerAvina Rami, Caiwei Zhong, Miguel Muniz, et al.
Biorxiv : the Preprint Server for Biology|March 13, 2023
A scalable, GMP-compatible, autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
Nature Communications|July 11, 2024
A scalable and cGMP-compatible autologous organotypic cell therapy for Dystrophic Epidermolysis BullosaGernot Neumayer, Jessica L Torkelson, Shengdi Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2024
Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO StudyGiacomo Montagna, Alison Laws, Massimo Ferrucci, et al.
Pageof 1